1.05
price down icon0.47%   -0.005
pre-market  Pre-market:  1.06   0.01   +0.95%
loading
Imunon Inc stock is traded at $1.05, with a volume of 87,574. It is down -0.47% in the last 24 hours and up +17.88% over the past month.
See More
Previous Close:
$1.055
Open:
$1.09
24h Volume:
87,574
Relative Volume:
0.56
Market Cap:
$15.42M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-0.5556
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
+0.96%
1M Performance:
+17.88%
6M Performance:
+5.02%
1Y Performance:
-40.00%
1-Day Range:
Value
$1.03
$1.10
1-Week Range:
Value
$1.01
$1.18
52-Week Range:
Value
$0.64
$3.65

Imunon Inc Stock (IMNN) Company Profile

Name
Name
Imunon Inc
Name
Phone
(609) 896-9100
Name
Address
997 LENOX DRIVE, LAWRENCEVILLE
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMNN's Discussions on Twitter

Compare IMNN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMNN
Imunon Inc
1.05 15.42M 500.00K -19.45M -18.22M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Imunon Inc Stock (IMNN) Latest News

pulisher
Apr 01, 2025

DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks

Apr 01, 2025
pulisher
Apr 01, 2025

Stacy Lindborg, PhD's Profile Page - Technology Networks

Apr 01, 2025
pulisher
Mar 31, 2025

Companies To Watch: Imunon - Life Science Leader

Mar 31, 2025
pulisher
Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research

Mar 28, 2025
pulisher
Mar 28, 2025

Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 07, 2025

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com

Mar 07, 2025
pulisher
Mar 03, 2025

Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance

Feb 27, 2025
pulisher
Feb 26, 2025

Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan

Feb 26, 2025
pulisher
Feb 22, 2025

Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily

Feb 20, 2025
pulisher
Feb 20, 2025

The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Feb 20, 2025
pulisher
Feb 19, 2025

Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial - StockTitan

Feb 19, 2025
pulisher
Feb 11, 2025

IMUNON names Douglas Faller as chief medical officer - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire

Feb 11, 2025
pulisher
Feb 10, 2025

Imunon names industry vet Douglas Faller as CMO - The Pharma Letter

Feb 10, 2025
pulisher
Feb 10, 2025

Imunon Appoints Dr. Douglas Faller as CMO - TipRanks

Feb 10, 2025
pulisher
Feb 10, 2025

Oncology Veteran Takes Helm at IMUNON as Phase 3 Trial ApproachesKey Details - Stock Titan

Feb 10, 2025
pulisher
Jan 30, 2025

Imunon director Donald Braun acquires $29,480 worth of shares - MSN

Jan 30, 2025
pulisher
Jan 26, 2025

Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Biotech's Target Price 183.757% Higher Than Current - Streetwise Reports

Jan 24, 2025
pulisher
Jan 07, 2025

Is Rigetti Computing Stock a Buy in 2025? - The Globe and Mail

Jan 07, 2025

Imunon Inc Stock (IMNN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):